



ASX Announcement

November 13th 2024

Atomo secures Australian order for supply of HIV Self-Tests

- **Order worth ~\$440k for the NAPWHA run HIV Self-Test mail-out program**
- **Scale up of public health funded HIV self-testing reflects growing market for sexual health testing in the home**

SYDNEY, Australia November 13th, 2024 - Atomo Diagnostics Limited (ASX:AT1) (Atomo) is pleased to announce securing a purchase order from the National Association of People with HIV Australia (NAPWHA) for approximately \$440k worth of HIV Self-Tests. Atomo considers the revenue from this order to be material.

This order supports ongoing scale up of a successful free-to-user HIV Self-Testing program run by NAPWHA, and now directly funded by the Federal Government under new public HIV health policy announced in the May budget.

The program is supported by Grindr, the world's largest social networking app for the LGBTIQ+ community, and expansion of the program ensures availability of more HIV Self-Tests and enable Grindr to continue to build awareness and providing their users with direct links to access self-testing resources in Australia.

Mr Kelly said, "We are delighted to see HIV self-testing continue to be an increasingly important public health channel for delivering decentralised HIV testing. We continue to work with NAPWHA and other partners here in Australia to ensure that discrete, convenient testing is available to those wishing to know their status".

Atomo supplies the only HIV Self-Test included on the Australian Register of Therapeutic Goods (ARTG) and has been instrumental in the implementation of a number of pilot programs, now being funded directly by the Federal and State Government.



This announcement was authorised by the Board of Directors.

For more information, please contact:

John Kelly
Atomo Diagnostics
john.kelly@atomodiagnostics.com
Phone: +61 401 922 279

About Atomo

Atomo is an Australian headquartered medical device company supplying unique, integrated rapid diagnostic test (RDT) devices to the global diagnostic market. Atomo's unique patented devices simplify testing procedures, enhance usability and improve reliability across rapid point-of-care (POC) and at-home testing applications. The Company has commercialised several products across international markets and has supply agreements in place for testing applications targeting infectious diseases including sexual health as well as female health.

See more at www.atomodiagnostics.com